These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 9539916

  • 1. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
    Kemp R, Miller J, Lungley S, Baker M.
    N Z Med J; 1998 Feb 27; 111(1060):50-3. PubMed ID: 9539916
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users.
    Robinson GM, Reynolds JN, Robinson BJ.
    N Z Med J; 1995 Mar 22; 108(996):103-5. PubMed ID: 7715873
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
    Chetwynd J, Brunton C, Blank M, Plumridge E, Baldwin D.
    N Z Med J; 1995 Sep 08; 108(1007):364-6. PubMed ID: 7566775
    [Abstract] [Full Text] [Related]

  • 4. [Risk factors for hepatitis C among injecting drug users in Oslo].
    Dalgard O, Egeland A, Ervik R, Vilimas K, Skaug K, Steen TW.
    Tidsskr Nor Laegeforen; 2009 Jan 15; 129(2):101-4. PubMed ID: 19151801
    [Abstract] [Full Text] [Related]

  • 5. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users.
    Brunton C, Kemp R, Raynel P, Harte D, Baker M.
    N Z Med J; 2000 Mar 24; 113(1106):98-101. PubMed ID: 10836310
    [Abstract] [Full Text] [Related]

  • 6. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
    Maher L, Chant K, Jalaludin B, Sargent P.
    J Gastroenterol Hepatol; 2004 Oct 24; 19(10):1114-20. PubMed ID: 15377287
    [Abstract] [Full Text] [Related]

  • 7. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
    Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL.
    Addiction; 2006 Oct 24; 101(10):1499-508. PubMed ID: 16968352
    [Abstract] [Full Text] [Related]

  • 8. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users.
    Mathei C, Shkedy Z, Denis B, Kabali C, Aerts M, Molenberghs G, Van Damme P, Buntinx F.
    J Viral Hepat; 2006 Aug 24; 13(8):560-70. PubMed ID: 16901287
    [Abstract] [Full Text] [Related]

  • 9. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore.
    Winslow M, Subramaniam M, Ng WL, Lee A, Song G, Chan YH.
    Singapore Med J; 2007 Jun 24; 48(6):504-8. PubMed ID: 17538746
    [Abstract] [Full Text] [Related]

  • 10. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B, Narayanan S, Navaratnam V.
    Drug Alcohol Rev; 2009 Jul 24; 28(4):447-54. PubMed ID: 19594801
    [Abstract] [Full Text] [Related]

  • 11. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
    Wand H, Spiegelman D, Law M, Jalaludin B, Kaldor J, Maher L.
    Addiction; 2009 Dec 24; 104(12):2049-56. PubMed ID: 19804463
    [Abstract] [Full Text] [Related]

  • 12. Hepatitis C prevalence and risk behavior of injecting drug users in Sydney: a continuing concern.
    Habib SE, Lovejoy FH, Aspin C.
    Southeast Asian J Trop Med Public Health; 2001 Dec 24; 32(4):823-34. PubMed ID: 12041560
    [Abstract] [Full Text] [Related]

  • 13. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M.
    BMC Infect Dis; 2006 Jun 08; 6():93. PubMed ID: 16762050
    [Abstract] [Full Text] [Related]

  • 14. [Prevalence of chronic viral hepatitis in drug abusers].
    Osztrogonácz H, Gerevich J, Horváth G, Tolvaj G, Dávid K.
    Orv Hetil; 2000 Apr 02; 141(14):715-8. PubMed ID: 10803013
    [Abstract] [Full Text] [Related]

  • 15. Prevalence of HIV, HCV and sexually transmitted infections among injecting drug users in Rawalpindi and Abbottabad, Pakistan: evidence for an emerging injection-related HIV epidemic.
    Platt L, Vickerman P, Collumbien M, Hasan S, Lalji N, Mayhew S, Muzaffar R, Andreasen A, Hawkes S.
    Sex Transm Infect; 2009 Apr 02; 85 Suppl 2():ii17-22. PubMed ID: 19307346
    [Abstract] [Full Text] [Related]

  • 16. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
    Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK.
    J Infect; 2009 May 02; 58(5):375-82. PubMed ID: 19328555
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
    Loebstein R, Mahagna R, Maor Y, Kurnik D, Elbaz E, Halkin H, Olchovsky D, Ezra D, Almog S.
    Isr Med Assoc J; 2008 Nov 02; 10(11):775-8. PubMed ID: 19070285
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.